Recently, several targeted therapeutics, including tyrosine kinase inhibitors, BCL2 inhibitors, IDH inhibitors, and antibody-drug conjugates, have been approved for the treatment of AML [41]. This evidence concerns the gene IDH1 and acute myeloid leukemia.